Compare · BLCO vs STAA
BLCO vs STAA
Side-by-side comparison of Bausch + Lomb Corporation (BLCO) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLCO and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- BLCO is the larger of the two at $5.80B, about 4.1x STAA ($1.42B).
- Over the past year, BLCO is up 18.7% and STAA is up 68.7% - STAA leads by 50.0 points.
- STAA has been more active in the news (9 items in the past 4 weeks vs 3 for BLCO).
- STAA has more recent analyst coverage (25 ratings vs 18 for BLCO).
- Company
- Bausch + Lomb Corporation
- STAAR Surgical Company
- Price
- $16.29+1.94%
- $28.46+4.06%
- Market cap
- $5.80B
- $1.42B
- 1M return
- +7.88%
- +0.25%
- 1Y return
- +18.73%
- +68.70%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 3
- 9
- Recent ratings
- 18
- 25
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest BLCO
- Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
- Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
- Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
- President, Surgical Bonnefoy Luc covered exercise/tax liability with 1,008 shares, decreasing direct ownership by 1% to 87,023 units (SEC Form 4) to satisfy tax liability
- SEC Form SD filed by Bausch + Lomb Corporation
- Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
- Director Von Eschenbach Andrew C. was granted 15,842 shares, increasing direct ownership by 22% to 86,656 units (SEC Form 4)
- Director Ross Thomas W. Sr. was granted 15,842 shares, increasing direct ownership by 23% to 85,233 units (SEC Form 4)
- Director Robertson Russel C was granted 15,842 shares, increasing direct ownership by 20% to 94,260 units (SEC Form 4)
- Director Paulson John was granted 15,842 shares, increasing direct ownership by 21% to 89,823 units (SEC Form 4)
Latest STAA
- SEC Form S-8 filed by STAAR Surgical Company
- SEC Form 4 filed by Director Wang Christopher Min Fang
- SEC Form 4 filed by Director Lebuhn Richard T.
- SEC Form 4 filed by Director Bradsher Neal C
- Director Butcher Arthur C converted options into 5,341 shares, increasing direct ownership by 127% to 9,549 units (SEC Form 4)
- SEC Form 4 filed by Director Zhou Lilian Yansheng
- STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Silverman Lou converted options into 10,683 shares, increasing direct ownership by 2,249% to 11,158 units (SEC Form 4)
- Director Jiang Wei converted options into 10,683 shares, increasing direct ownership by 16% to 77,127 units (SEC Form 4)
- Director Zhou Lilian Yansheng was granted 3,530 shares, increasing direct ownership by 77% to 8,101 units (SEC Form 4)